Open Access

Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells

  • Authors:
    • So-Hee Han
    • Jae-Han Lee
    • Joong-Seok Woo
    • Gi-Hwan Jung
    • Soo-Hyun Jung
    • Eun-Ji Han
    • Young-Seok Park
    • Byeong-Soo Kim
    • Sang-Ki Kim
    • Byung-Kwon Park
    • Changsun Choi
    • Ji-Youn Jung
  • View Affiliations

  • Published online on: February 25, 2022     https://doi.org/10.3892/ijmm.2022.5110
  • Article Number: 54
  • Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Myricetin, a flavonoid found in fruits and vegetables, is known to have antioxidant and anticancer effects. However, the anticancer effects of myricetin on SK‑BR‑3 human breast cancer cells have not been elucidated. In the present study, the anticancer effects of myricetin were confirmed in human breast cancer SK‑BR‑3 cells. As the concentration of myricetin increased, the cell viability decreased. DAPI (4',6‑diamidino‑2‑phenylindole) and Annexin V/PI staining also revealed a significant increase in apoptotic bodies and apoptosis. Western blot analysis was performed to confirm the myricetin‑induced expression of apoptosis‑related proteins. The levels of cleaved PARP and Bax proteins were increased, and that of Bcl‑2 was decreased. The levels of proteins in the mitogen‑activated protein kinase (MAPK) pathway were examined to confirm the mechanism of myricetin‑induced apoptosis, and it was found that the expression levels of phosphorylated c‑Jun N‑terminal kinase (p‑JNK) and phosphorylated mitogen‑activated protein kinases (p‑p38) were increased, whereas that of phosphorylated extracellular‑regulated kinase (p‑ERK) was decreased. It was also demonstrated that myricetin induced autophagy by promoting autophagy‑related proteins such as microtubule‑associated protein 1A/1B‑light chain 3 (LC 3) and beclin 1. In addition, 3‑methyladenine (3‑MA) was used to evaluate the association between cell viability and autophagy in cells treated with myricetin. The results showed that simultaneous treatment with 3‑MA and myricetin promoted the apoptosis of breast cancer cells. Furthermore, treatment with a JNK inhibitor reduced cell viability, promoted Bax expression, and reduced the expression of p‑JNK, Bcl‑2, and LC 3‑II/I. These results suggest that myricetin induces apoptosis via the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells. In conclusion, myricetin shows potential as a natural anticancer agent in SK‑BR‑3 cells.
View Figures
View References

Related Articles

Journal Cover

April-2022
Volume 49 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han S, Lee J, Woo J, Jung G, Jung S, Han E, Park Y, Kim B, Kim S, Park B, Park B, et al: Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells. Int J Mol Med 49: 54, 2022.
APA
Han, S., Lee, J., Woo, J., Jung, G., Jung, S., Han, E. ... Jung, J. (2022). Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells. International Journal of Molecular Medicine, 49, 54. https://doi.org/10.3892/ijmm.2022.5110
MLA
Han, S., Lee, J., Woo, J., Jung, G., Jung, S., Han, E., Park, Y., Kim, B., Kim, S., Park, B., Choi, C., Jung, J."Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells". International Journal of Molecular Medicine 49.4 (2022): 54.
Chicago
Han, S., Lee, J., Woo, J., Jung, G., Jung, S., Han, E., Park, Y., Kim, B., Kim, S., Park, B., Choi, C., Jung, J."Myricetin induces apoptosis through the MAPK pathway and regulates JNK‑mediated autophagy in SK‑BR‑3 cells". International Journal of Molecular Medicine 49, no. 4 (2022): 54. https://doi.org/10.3892/ijmm.2022.5110